Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK/PD of Ponezumab in Mild to Moderate Alzheimer's Disease
NCT00945672Phase 2Completed
- Sponsor
- Pfizer
- Start
- Aug 2009
- Primary completion
- Jun 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ponezumab in Alzheimer's disease (AD) (3 arms), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events (AEs) or Serious Adverse Events (SAEs), Number of Participants With Change From Baseline in Brain Magnetic Resonance Imaging (MRI) Abnormalities at Month 18 and 5 more. Started Aug 2009; status: completed.
02
Drugs
ponezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00945672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00945672.